Astragaloside IV protects against cardiac hypertrophy via inhibiting the ca2+/CaN signaling pathway

Planta Medica

Volumn 80, Issue 1, 2014, Pages 63-69

  Lu, Meili ^a   Wang, Hongxin ^a   Wang, Jing ^a   Zhang, Jing ^a   Yang, Juan ^a   Liang, Lingjun ^a   Maslov, Leonid N ^b  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b CARDIOLOGY RESEARCH INSTITUTE   (Russian Federation)

Author keywords

astragaloside IV; calcineurin; calcium; cardiac hypertrophy

Indexed keywords

ASTRAGALOSIDE IV; CALCINEURIN; CALCIUM; LIPOPOLYSACCHARIDE; MESSENGER RNA; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NFAT3; VERAPAMIL;

ACTIN FILAMENT; ANTIHYPERTROPHIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL GROWTH; CELL SIZE; CELL VOLUME; CONTROLLED STUDY; CYTOPLASM; DRUG ACTIVITY; DRUG INHIBITION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IMMUNOFLUORESCENCE; IN VIVO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CALCINEURIN; CALCIUM SIGNALING; CARDIOMEGALY; CARDIOTONIC AGENTS; CELLS, CULTURED; DRUGS, CHINESE HERBAL; LIPOPOLYSACCHARIDES; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NFATC TRANSCRIPTION FACTORS; RATS; SAPONINS; SIGNAL TRANSDUCTION; TRITERPENES;

EID: 84892437287     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0033-1360129     Document Type: Article

References (36)

1. Li M., Yu L., She T., Gan Y., Liu F., Hu Z., Chen Y., Li S., Xia H. Astragaloside IV attenuates Toll-like receptor 4 expression via NF- κ B pathway under high glucose condition in mesenchymal stem cells. Eur J Pharmacol: 2012; 696 203 209
2. Yu J., Zhang Y., Sun S., Shen J., Qiu J., Yin X., Yin H., Jiang S. Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats. Can J Physiol Pharmacol: 2006; 84 579 587 (Pubitemid 44605721)
3. Chen X., Peng L. H., Shan Y. H., Li N., Wei W., Yu L., Li Q. M., Liang W. Q., Gao J. Q. Astragaloside IV-loaded nanoparticle-enriched hydrogel induces wound healing and anti-scar activity through topical delivery. Int J Pharm: 2013; 447 171 181
4. Gao X. H., Xu X. X., Pan R., Li Y., Luo Y. B., Xia Y. F., Murata K., Matsuda H., Dai Y. Matsu-Saponin fraction from Astragalus membranaceus roots protects mice against polymicrobial sepsis induced by cecal ligation and puncture by inhibiting inflammation and upregulating protein C pathway. J Nat Med: 2009; 63 421 429
5. Qiu L. H., Xie X. J., Zhang B. Q. Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation. Biol Pharm Bull: 2010; 33 641 646
6. Wang S., Li J., Huang H., Gao W., Zhuang C., Li B., Zhou P., Kong D. Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali. Biol Pharm Bull: 2009; 32 132 135
7. Li X., Wang X., Han C., Wang X., Xing G., Zhou L., Li G., Niu Y. Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p 38 MAPK pathway. Free Radic Biol Med: 2013; 60 168 176
8. Chan W. S., Durairajan S. S., Lu J. H., Wang Y., Xie L. X., Kum W. F., Koo I., Yung K. K., Li M. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. Neurochem Int: 2009; 55 414 422
9. Zhang W. D., Chen H., Zhang C., Liu R. H., Li H. L., Chen H. Z. Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro. Planta Med: 2006; 72 4 8 (Pubitemid 43241585)
10. Wu X., Cao Y., Nie J., Liu H., Lu S., Hu X., Zhu J., Zhao X., Chen J., Chen X., Yang Z., Li X. Genetic and pharmacological inhibition of Rheb1-mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice. Am J Pathol: 2013; 182 2005 2014
11. Zhao J., Yang P., Li F., Tao L., Ding H., Rui Y., Cao Z., Zhang W. Therapeutic effects of astragaloside IV on myocardial injuries: multi-target identification and network analysis. PLoS One: 2012; 7 e44938
12. Zhao M., Zhao J., He G., Sun X., Huang X., Hao L. Effects of astragaloside IV on action potentials and ionic currents in guinea-pig ventricular myocytes. Biol Pharm Bull: 2013; 36 515 521
13. Meng D., Chen X. J., Bian Y. Y., Li P., Yang D., Zhang J. N. Effect of astragalosides on intracellular calcium overload in cultured cardiac myocytes of neonatal rats. Am J Chin Med: 2005; 33 11 20 (Pubitemid 40468299)
14. Xu X. L., Ji H., Gu S. Y., Shao Q., Huang Q. J., Cheng Y. P. Modification of alterations in cardiac function and sarcoplasmic reticulum by astragaloside IV in myocardial injury in vivo. Eur J Pharmacol: 2007; 568 203 212 (Pubitemid 46976897)
15. Xu X. L., Chen X. J., Ji H., Li P., Bian Y. Y., Yang D., Xu J. D., Bian Z. P., Zhang J. N. Astragaloside IV improved intracellular calcium handling in hypoxia-reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase. Pharmacology: 2008; 81 325 332 (Pubitemid 351666921)
16. Chow J. C., Young D. W., Golenbock D. T., Christ W. J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem: 1999; 274 10689 10692
17. Yang R. B., Mark M. R., Gray A., Huang A., Xie M. H., Zhang M., Goddard A., Wood W. I., Gurney A. L., Godowski P. J. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature: 1998; 395 284 288 (Pubitemid 28447554)
18. Liu C. J., Cheng Y. C., Lee K. W., Hsu H. H., Chu C. H., Tsai F. J., Tsai C. H., Chu C. Y., Liu J. Y., Kuo W. W., Huang C. Y. Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signaling pathway in H9c2 myocardiac cells. Mol Cell Biochem: 2008; 313 167 178
19. Singh M. V., Swaminathan P. D., Luczak E. D., Kutschke W., Weiss R. M., Anderson M. E. MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. J Mol Cell Cardiol: 2012; 52 1135 1144
20. Thompson M., Kliewer A., Maass D., Becker L., White D. J., Bryant D., Arteaga G., Horton J., Giroir B. P. Increased cardiomyocyte intracellular calcium during endotoxin-induced cardiac dysfunction in guinea pigs. Pediatr Res: 2000; 47 669 676 (Pubitemid 30249858)
21. Ren J., Avery J., Zhao H., Schneider J. G., Ross F. P., Muslin A. J. Beta3 Integrin deficiency promotes cardiac hypertrophy and inflammation. J Mol Cell Cardiol: 2007; 42 367 377 (Pubitemid 46135609)
22. Heymans S., Hirsch E., Anker S. D., Aukrust P., Balligand J. L., Cohen-Tervaert J. W., Drexler H., Filippatos G. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail: 2009; 11 119 129
23. Saito T., Fukuzawa J., Osaki J., Sakuragi H., Yao N., Haneda T., Fujino T., Wakamiya N., Kikuchi K., Hasebe N. Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy. J Mol Cell Cardiol: 2003; 35 1153 1160 (Pubitemid 37083259)
24. Fu M., Zhang J., Xu S., Pang Y., Liu N., Tang C. Role of calcineurin in angiotensin II-induced cardiac myocyte hypertrophy of rats. Chin Med Sci J: 2001; 16 1 4
25. Lu C. C., Xu Y. Q., Wu J. C., Hang P. Z., Wang Y., Wang C., Wu J. W., Qi J. C., Zhang Y., Du Z. M. Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways. Naunyn Schmiedebergs Arch Pharmacol: 2013; 386 747 755
26. Zhu W., Zou Y., Shiojima I., Kudoh S., Aikawa R., Hayashi D., Mizukami M., Toko H., Shibasaki F., Yazaki Y., Nagai R., Komuro I. Ca2+/calmodulin- dependent kinase II and calcineurin play critical roles in endothelin-1-induced cardiomyocyte hypertrophy. J Biol Chem: 2000; 275 15239 15245 (Pubitemid 30337249)
27. Wang G. J., Wang H. X., Yao Y. S., Guo L. Y., Liu P. The role of Ca2+/calmodulin-dependent protein kinase II and calcineurin in TNF- α -induced myocardial hypertrophy. Braz J Med Biol Res: 2012; 45 1045 1051
28. Wang H. Y., Liu X. Y., Han G., Wang Z. Y., Li X. X., Jiang Z. M., Jiang C. M. LPS induces cardiomyocyte injury through calcium-sensing receptor. Mol Cell Biochem: 2013; 379 153 159
29. Zhang T., Lu X., Li J., Chidiac P., Sims S. M., Feng Q. Inhibition of Na/K-ATPase promotes myocardial tumor necrosis factor-alpha protein expression and cardiac dysfunction via calcium/mTOR signaling in endotoxemia. Basic Res Cardiol: 2012; 107 254
30. Suzuki J., Bayna E., Li H. L., Molle E. D., Lew W. Y. Lipopolysaccharide activates calcineurin in ventricular myocytes. J Am Coll Cardiol: 2007; 49 491 499 (Pubitemid 46135886)
31. Yang J., Wang H. D., Lu D. X., Wang Y. P., Qi R. B., Li J., Li F., Li C. J. Effects of neutral sulfate berberine on LPS-induced cardiomyocyte TNF- α secretion, abnormal calcium cycling, and cardiac dysfunction in rats1. Acta Pharmacol Sin: 2006; 27 173 178 (Pubitemid 43171155)
32. Xu X. L., Ji H., Gu S. Y. Protective effects of astragaloside on isoproterenol induced cardiac hypertrophy in mice. J China Pharm Univ: 2007; 38 451 455 (Pubitemid 350081387)
33. Wang J., Liu J. H., Yao P. Protective effect of astragaloside IV on isoproterenol induced myocardial injury. J Shanghai Jiaotong Univ (Medical Science): 2007; 27 384 386
34. Zhao Z., Wang W., Wang F., Zhao K., Han Y., Xu W., Tang L. Effects of Astragaloside IV on heart failure in rats. Chin Med: 2009; 4 6
35. Wu X., Cao Y., Nie J., Liu H., Lu S., Hu X., Zhu J., Zhao X., Chen J., Chen X., Yang Z., Li X. Genetic and pharmacological inhibition of Rheb1-mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice. Am J Pathol: 2013; 182 2005 2014
36. Lu M., Wang H., Yang Y., Zhang L., Liu C., Yang J., Wong T. M. The function of calcineurin and ERK1/2 signal in the antihypertrophic effects of kappa-opioid receptor stimulation on myocardial hypertrophy induced by isoprenaline. Pharmazie: 2012; 67 182 186